• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Integrated Genomic and Epidemiological Surveillance to Monitor SARS-CoV-2 Variants in Italy: Insights From the JN.1 Case Study (2023-

tetano

Editor, Senior Moderator
J Med Virol


. 2026 Jan;98(1):e70775.
doi: 10.1002/jmv.70775.
Integrated Genomic and Epidemiological Surveillance to Monitor SARS-CoV-2 Variants in Italy: Insights From the JN.1 Case Study (2023-2024)

Mattia Manica[SUP] 1 [/SUP], Emanuela Giombini[SUP] 2 [/SUP], Martina Del Manso[SUP] 2 [/SUP], Carla Molina Grané[SUP] 1 [/SUP], Luigina Ambrosio[SUP] 2 [/SUP], Antonino Bella[SUP] 2 [/SUP], Angela di Martino[SUP] 2 [/SUP], Daniele Petrone[SUP] 2 [/SUP], Flavia Riccardo[SUP] 2 [/SUP], Piero Poletti[SUP] 1 [/SUP], Patrizio Pezzotti[SUP] 2 [/SUP], Anna Teresa Palamara[SUP] 2 [/SUP], Stefano Merler[SUP] 1 [/SUP], Paola Stefanelli[SUP] 2 [/SUP]


Affiliations
Abstract

The epidemiology of SARS-CoV-2 is marked by the continuous emergence of new lineages. Early detection and assessment of their transmissibility can be challenging for surveillance systems that rely solely on case time series data. Genomic surveillance, focusing on identifying and characterizing circulating variants, can provide early insights into their epidemiological impact. Phylogenetic and phylodynamic methods were applied to sequence data collected between October 2023 and January 2024 to study the transmission of the JN.1 variant in Italy. The genomic surveillance encompassed two data flows: flash surveys estimating variant prevalence and continuous sampling to identify emerging variants. We estimated the effective reproduction number (R[SUB]e[/SUB]) of JN.1 using a phylodynamic birth-death model. Results were compared with the daily net reproduction number (R[SUB]t[/SUB]) of SARS-CoV-2 estimated from time series of hospital admissions recorded through epidemiological surveillance. We traced back the appearance of JN.1 in Italy to October 2023, with subvariants emerging and co-circulating shortly thereafter. JN.1 became dominant nationwide by the end of 2023. According to phylodynamic analysis, the R[SUB]e[/SUB] of JN.1 was 1.73 (95% CI: 1.36-2.28) in mid-November, and its transmissibility declined over the following months. This trend aligned with R[SUB]t[/SUB] estimates from epidemiological surveillance, encompassing all co-circulating lineages. The high transmissibility of JN.1 anticipated the rise in its prevalence in the population and showed a temporal correlation with a transient increase in COVID-19 hospitalizations. Integrating genomic and epidemiological surveillance enhances pathogen monitoring and the assessment of new lineages' transmissibility, providing complementary evidence to patterns observed through standard surveillance.

Keywords: Genetics; SARS coronavirus; Virus classification; epidemiology.

 
Back
Top Bottom